Elaine Drobny, MD
Endocrinology, Diabetes & Metabolism · Milwaukee, WINPI 1265488365
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Novo Nordisk at 56.2% of the total. Reporting peaked in 2019 at $20,187 and has fallen 95.6% since, to $889 in 2025. Among endocrinology, diabetes & metabolism clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $150.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$17K
- Johnson & Johnson$5K
- IBSA Pharma Inc.$4K
- Sanofi-aventis U.S. LLC$766
- Amgen$619
- AstraZeneca$579
- plus $2K from 17 others
What the payments were for
- Consulting fees$3,37511%
- Speaking & faculty fees$16,01954%
- Travel & lodging$2,1747%
- Food & beverage$7,80227%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 78 | $16,528 |
| Johnson & Johnson | 8 | $5,219 |
| IBSA Pharma Inc. | 24 | $3,618 |
| Sanofi-aventis U.S. LLC | 14 | $766 |
| Amgen(2 entities) | 10 | $619 |
| AstraZeneca | 10 | $579 |
| Medtronic(2 entities) | 14 | $413 |
| Dexcom, Inc. | 5 | $363 |
| Lilly USA, LLC | 3 | $162 |
| Tandem Diabetes Care, Inc. | 1 | $159 |
| Halozyme Inc | 2 | $141 |
| Ascendis Pharma Endocrinology Inc | 3 | $135 |
| Boehringer Ingelheim | 1 | $125 |
| Abbott | 8 | $119 |
| Nestle Healthcare Nutrition Inc. | 1 | $115 |
| Gilead | 1 | $96 |
| Xeris Pharmaceuticals, Inc. | 4 | $83 |
| Amneal Pharmaceuticals LLC | 4 | $71 |
| Sequel Med Tech, LLC | 1 | $25 |
| Radius Health, Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tresiba$13,280
- INVOKANA$5,055
- Tirosint$4,797
- Ozempic$555
- RYBELSUS$458
- TEPEZZA$378
- SOLIQUA 100/33$277
- FARXIGA$256
- DEXCOM G6 TRANSMITTER$233
- t:slim X2 Insulin Pump with Control-IQ$159
- EVENITY$125
- Saxenda$125
- JARDIANCE$125
- TLANDO$124
- XYOSTED$124
- Victoza$124
- Xultophy 100/3.6$124
- TZIELD$122
- MOUNJARO$117
- ZENPEP$115
How this compares
$29,408 in reported general payments places this provider in the 90th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $119,183 |
| TrulicityDulaglutide | 43 | $63,843 |
| ForteoTeriparatide | 13 | $55,799 |
| TradjentaLinagliptin | 48 | $48,356 |
| JardianceEmpagliflozin | 47 | $47,235 |
| MounjaroTirzepatide | 24 | $28,858 |
| JanuviaSitagliptin Phosphate | 26 | $28,293 |
| InvokanaCanagliflozin | 24 | $26,521 |
| RybelsusSemaglutide | 17 | $25,020 |
| Humalog Kwikpen U-100Insulin Lispro | 58 | $19,790 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $19,622 |
| FarxigaDapagliflozin Propanediol | 13 | $18,641 |
| SynthroidLevothyroxine Sodium | 142 | $14,652 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 87 | $13,930 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 44 | $13,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Forteo, Mounjaro, Humalog, Insulin Lispro | $162 | $162,767148 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $16,528 | $147,936111 claims |
| Boehringer IngelheimTradjenta, Jardiance | $125 | $95,59195 claims |
| Johnson & JohnsonInvokana | $5,219 | $26,52124 claims |
| AstraZenecaFarxiga | $579 | $18,64113 claims |
| IBSA Pharma Inc.Tirosint | $3,618 | $3,61117 claims |
| Sanofi-aventis U.S. LLCLantus | $766 | $2,31417 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $71 | $1,563168 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
Other endocrinology, diabetes & metabolism in Milwaukee
- Denise Teves QuallerMilwaukee$56K
- Adriana IoachimescuMilwaukee$26K
- Catherine ZhangMilwaukee$16K
- Timur GusovMilwaukee$5K
- Antoni GofronMilwaukee$5K
- Anil ChandelMilwaukee$3K
- Michael VossMilwaukee$2K
- Olena KlindukhovaMilwaukee$1K
- Usonwanne IbekweMilwaukee$1K
- Veitla RaoMilwaukee$658
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.